Abstract
Sixty-five patients with high-risk trophoblast disease have been treated with the EMACO combination split regimen therapy in the 10 year period, 1981 to 1990. Four patients died but the remaining 61 (94%) remain free of disease up to 10 years later. Toxicity was manageable in most cases with minimal delay in treatment from myelosuppression. EMACO is a well tolerated regimen with a high cure rate in patients with high-risk gestational trophoblast disease (GTD).
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Australia
-
Cyclophosphamide / administration & dosage
-
Dactinomycin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Methotrexate / administration & dosage
-
Middle Aged
-
Pregnancy
-
Risk
-
Trophoblastic Neoplasms / drug therapy*
-
Uterine Neoplasms / drug therapy*
-
Vincristine / administration & dosage
Substances
-
Dactinomycin
-
Vincristine
-
Etoposide
-
Cyclophosphamide
-
Methotrexate